Rapport Therapeutics Reports Q3 2026 Net Loss of $40.2 Million

Gotrade News - Rapport Therapeutics (RAPP) reported a third-quarter 2026 net loss of $40.2 million, compared with $26.9 million a year earlier, according to the company's official release filed with the SEC on Wednesday, November 4, 2026. The company said it has cash runway through the end of 2029.

RAPP Market Data

Regular-session close on November 4, 2026, New York time. Prices and changes: Yahoo Finance, cross-checked against the closing price on Nasdaq.com. Market cap: that close times the shares outstanding on the latest 10-Q or 10-K cover (SEC EDGAR).

Rapport Therapeutics Earnings Details

For the quarter ended September 30, 2026, research and development expense was $34.3 million, compared with $22.3 million in the prior year period, and selling, general and administrative expense was $9.8 million, compared with $7.7 million, the company said. Rapport attributed the R&D increase mainly to clinical development costs for its lead drug candidate, RAP-219, including its Phase 3 program in focal onset seizures (FOS) and the completion of its Phase 2 trial in bipolar mania.

The company ended the quarter with $395.0 million in cash, cash equivalents and short-term investments, excluding restricted cash, compared with $436.1 million as of June 30, 2026. In October 2026 it completed a public offering of common stock at $21.00 per share, an offering of 2.25% convertible senior notes due 2032 and a concurrent private placement, with aggregate net proceeds of approximately $410.7 million. It also sold approximately $10 million of stock under its at-the-market program in November 2026. Including those proceeds, Rapport estimated, on an unaudited basis, $815.4 million in cash and cash equivalents as of November 3, 2026.

Why It Matters for RAPP

Rapport is a clinical-stage biotechnology company. On October 20, 2026, it reported that its Phase 2 trial of RAP-219 in adults with bipolar I disorder experiencing an acute manic episode met its primary endpoint, a 3.1-point placebo-adjusted improvement in Young Mania Rating Scale total score at Week 3. Chief executive Abraham N. Ceesay called the results "transformational for Rapport" and said the company is "well funded to deliver on the catalysts ahead."

The company said it plans to meet with the U.S. Food and Drug Administration in the first quarter of 2027 to discuss the Phase 2 data and registrational trial design, and expects to start two Phase 3 trials in acute bipolar mania in the second half of 2027. It also expects initial data from an open-label long-term safety trial in FOS in the fourth quarter of 2026.

This article is for education and information only and is not investment advice. Investment decisions are yours to make after your own research.

This article was written with the help of AI and checked by the Gotrade team before publishing.

Sources

• Rapport Therapeutics Form 8-K, Exhibit 99.1 (SEC EDGAR)